Stay updated with breaking news from Technologies Munich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
Investigator-initiated multicenter Phase I study in glioblastoma with CAXII-targeting, 177Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of Münster as the sponsor
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40th
Grand Pharma has licensed the development, manufacturing and commercialization rights of ITM's Targeted Radionuclide Therapeutic candidates ITM-11 (n.c.a 177Lu-edotreotide) and ITM-41 (n.c.a 177Lu-zoledronate)
Press release content from Business Wire. The AP news staff was not involved in its creation.